Know the Latest MASH Treatment Options

April 2026

The latest indication for injectable semaglutide (Wegovy) will increase focus on metabolic dysfunction-associated steatohepatitis (MASH).

About 15 million adults in the US have MASH...and it’s on the rise.

We know MASH can progress to fibrosis, cirrhosis, or liver failure.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote